Pharmacoeconomic evaluation of Keluoxin capsule combined with chemical medicine in the treatment of diabetic kidney disease
- VernacularTitle:渴络欣胶囊联用化学药治疗糖尿病肾病的药物经济学评价
- Author:
Chang LIU
1
;
Libo TAO
1
;
Hao LU
2
;
Housheng KANG
3
;
Wei LI
4
;
Yin LIU
5
;
Yanming XIE
6
;
Xin CUI
6
Author Information
1. Center for Health Policy and Technology Evaluation，Peking University Health Science Center，Beijing 100191，China
2. Dept. of Endocrinology，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 200021，China
3. Dept. of Endocrinology，the Affiliated Hospital of North Sichuan Medical College，Sichuan Nanchong 637000，China
4. Dept. of Nephrology，Affiliated Hospital of Shandong University of Traditional Chinese Medicine，Jinan 250011，China
5. Dept. of Clinical Medicine，North Sichuan Medical College，Sichuan Nanchong 637100，China
6. Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Scienc es，Beijing 100700，China
- Publication Type:Journal Article
- Keywords:
Keluoxin capsule;
diabetic kidney disease
- From:
China Pharmacy
2022;33(17):2124-2128
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluat e the cost-effectiveness of Keluoxin capsule combi ned with chemical medicine in the treatment of diabetic kidney disease （DKD）from the perspective of the whole society. METHODS Six-state Markov model with 1 year cycle and 40 years time horizon was constructed by means of secondary literature review ，medical record analysis of sample hospital and clinical expert consultation. The cost-effectiveness of Keluoxin capsule combined with chemical medicine versus chemical medicine alone for DKD was evaluated by taking the quality-adjusted life year （QALY）as the output index ，setting the discount rate as 5％，and taking one time domestic gross domestic product （GDP）per capita in 2020 of China as the judgement threshold of incremental cost-effectiveness ratio （ICER）. RESULTS Within 40 years，Keluoxin capsule combined with chemical medicine group spent 8 644.09 yuan per capita more than chemical medicine alone group ，and gained more 0.143 QALYs；ICER was 60 460.25 yuan/QALY，which was less than one times GDP per capita of China in 2020（72 447 yuan）. The results of sensitivity analysis showed that the annual days of using Keluoxin capsule ，the health utility value of DKD at early stage had a great influence on the results of cost-effectiveness analysis. The results of probabilistic sensitivity analysis suggested that the basic analysis results of this study were robust. CONCLUSIONS At the current price level ，Keluoxin capsule combined with chemical medicine is more cost-effective to treat DKD than chemical medicine alone. The dosage of Keluoxin capsule and health utility value should be paid attention in specific decision- bjmu.edu.cn making scenarios.
